Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl

Friday, October 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Emergent BioSolutions has announced the retirement of CFO Richard S. Lindahl, effective December 31, 2026. Frank Vargo will take over as interim CFO starting January 1, 2027. To ensure a smooth transition, Lindahl will serve as a senior executive advisor until March 31, 2027.

Market Sentiment Analysis

POSITIVE FACTORS

  • Richard S. Lindahl's retirement indicates a planned transition.
  • Frank Vargo is prepared to step into the CFO role.
  • Rich will assist in the transition as a senior executive advisor.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
COVID-HIG
Phase 1 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role of interim chief financial officer effective January 1, 2027. To support a seamless transition, Rich will serve as a senior executive advisor from January 1 through March 31, 2027. “On behalf of the Board of Direc

Frequently Asked Questions

When will Richard S. Lindahl retire?

Richard S. Lindahl will retire on December 31, 2026.

Who will replace Richard Lindahl as CFO?

Frank Vargo will assume the role of interim CFO starting January 1, 2027.

What will Richard Lindahl do after retirement?

He will serve as a senior executive advisor from January 1 to March 31, 2027.

ShareAdd on Google
Tags: EBS Emergent BioSolutions Richard Lindahl Frank Vargo CFO transition executive retirement
Last updated: Oct 16, 2026

Biotech snapshot

Cash runway
$140M liquidity · $0M/mo burn
Low dilution risk
Lead asset
COVID-HIGPhase 1
SARS-CoV-2 Infection →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →